gutflix
GI learning, personalised

Summary

OPTIMIZED DUAL THERAPY WITH TEGOPRAZAN AND HIGH-DOSE AMOXICILLIN FOR HELICOBACTER PYLORI ERADICATION: A REAL-WORLD PILOT STUDY

william Otero

UEG Week Barcelona 2026 Poster

Oesophagus

October 19, 2026

A prospective pilot study of 28 patients found that a 14-day dual regimen of tegoprazan 50 mg three times daily with weight-based high-dose amoxicillin achieved 96.4% Helicobacter pylori eradication, significantly exceeding the 85% historical benchmark.

KEY POINTS

- The eradication rate was 96.4% (27/28 patients; 95% CI 81.7–99.9), significantly higher than the historical benchmark of 85% ($p < 0.001$).
- Adverse events were mild and occurred in 14.3% of patients, including headache (7.1%), diarrhea (3.6%), and abdominal distension (3.6%), with no serious adverse events or treatment discontinuations.
- The regimen consisted of tegoprazan 50 mg three times daily combined with weight-based amoxicillin (50 mg/kg/day divided into four doses) for 14 days.
- Eradication was assessed by 13C-urea breath test 4 weeks after treatment completion in adults with histologically confirmed H. pylori infection.
- The authors state that larger controlled studies are warranted to confirm these findings from this real-world pilot study.

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/065f149c-d12a-11f1-a1ed-daaa6dbee0a2

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.